Stockscreener 앱 받기
60.02
1.90%
1.12
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Why Bristol-Myers Squibb Co. (BMY) Went Up On Friday? - Insider Monkey
BMS secures pair of EU recommendations for Opdivo, including injectable form - FirstWord Pharma
Bristol Myers Squibb (BMY) Receives EMA Panel Approval Recommendation for Opdivo - GuruFocus.com
Bristol Myers Squibb gets positive CHMP opinion for neoadjuvant Opdivo and chemotherapy - Seeking Alpha
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications - BioSpace
European committee backs subcutaneous formulation of Bristol Myers’ Opdivo By Investing.com - Investing.com Australia
European committee backs subcutaneous formulation of Bristol Myers’ Opdivo - Investing.com
Outgoing Bristol-Myers GC Saw Comp Rise To $7M - Law360
UBS maintains neutral Bristol-Myers stock with $60 target By Investing.com - Investing.com UK
The Escalator: Bristol Myers Squibb, Editas Medicine, Takeda and more - MM+M Online
Why Pfizer Is My Largest Healthcare Position - The Motley Fool
Bristol-Myers Squibb Says Board Chair & CEO Christopher S. Boerner's 2024 Total Compensation Was $18.8 MillionSEC Filing - Marketscreener.com
SEC Spurns Bristol Myers Bid to Stop Voting on Anti-DEI Plan - Bloomberg Law
Four New Studies Demonstrate that Viz.ai Finds New Patients with Hypertrophic Cardiomyopathy Earlier When Embedded into the Clinical Workflow - Quantisnow
Predict First: BMS Executives Discuss Company’s AI Approach - Genetic Engineering & Biotechnology News
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold (NYSE:BMY) - Seeking Alpha
Bristol-Myers Squibb expands immuno-oncology pipeline with Flexus Biosciences, Rigel Pharmaceuticals deals - FirstWord Pharma
Bristol-Myers Squibb’s SWOT analysis: stock faces legacy challenges amid growth potential - Investing.com
Is Bristol-Myers Squibb (BMY) The Best Healthcare Dividend Stock to Invest in? - Insider Monkey
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Is Bristol-Myers Squibb (BMY) Among the Cheap Stocks to Buy According to Billionaires? - Insider Monkey
Bristol-Myers Squibb Company (BMY): Among Incredibly Cheap Dividend Stock to Buy Now - Insider Monkey
Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy (NYSE:MRK) - Seeking Alpha
Layoff Tracker: Vaxart Cuts 10% of Staff After US Government Orders Vaccine Trial Halt - BioSpace
Is Bristol-Myers Squibb Company (BMY) The Best Undervalued Stock to Buy According to Billionaires? - Insider Monkey
Bristol Myers Squibb Names GM for Saudi Arabia and Gulf Countries - Contract Pharma
Bristol Myers Squibb Appoints Osama Braiwish as General Manager for Saudi Arabia & Gulf Countries - The Malaysian Reserve
Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note - Yahoo Finance
Is Bristol-Myers Squibb (BMY) the Most Undervalued Biotech Stock to Invest In? - Insider Monkey
Bristol-Myers Squibb: Why I'm Still Bullish (NYSE:BMY) - Seeking Alpha
7 Most Undervalued Biotech Stocks To Invest In - Insider Monkey
Bristol-Myers Squibb Company (BMY): A Bull Case Theory - Yahoo Finance UK
EC approves Bristol Myers Squibb’s follicular lymphoma CAR T therapy - Yahoo Finance
StockWatch: Will BMS–2seventy Deal Prove a Win-Win? - Genetic Engineering & Biotechnology News
Why Bristol-Myers Squibb Company (BMY) Went Down On Thursday? - Insider Monkey
Why Bristol-Myers Squibb Company (BMY) Went Down On Friday? - Yahoo Finance
Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer - Benzinga
Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment - Yahoo Finance
European Commission expands approval for Bristol Myers Squibb’s lymphoma therapy By Investing.com - Investing.com South Africa
European Commission expands approval for Bristol Myers Squibb’s lymphoma therapy - Investing.com
Bristol Myers Squibb’s Breyanzi gets EU nod for lymphoma treatment - Investing.com
Bristol Myers Squibb Receives Approval From The European Commission To Expand Use Of Car T Cell Therapy Breyanzi For Relapsed Or Refractory Follicular Lymphoma - Marketscreener.com
Bristol Myers Squibb to acquire 2seventy bio for USD 286 million - Medical Dialogues
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst - Benzinga
Bristol Meyers Squibb to Acquire 2seventy bio - Contract Pharma
Bristol Myers Squibb Sets Critical Q1 Earnings Date: What Investors Should Mark on Their Calendar - StockTitan
1.66%
자본화:
|
볼륨(24시간):